At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer.
BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer
9th December 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?